Vendor comparison · 2026
Mazdutide vendors: 1 compared on COAs and price
MetabolicAlso known as IBI362, LY3305677
Evidence tier
Moderate published literature
50 publications over 5 years · trials not yet curated
- Vendors carrying it
- 1
- 1 with a listed price
- Vendors with checkable COAs
- 0
- 0 publish any certificate
- Lots tested
- 0
- 0 naming a checkable lab
- Independent assays
- 0
- none on file yet
- Newest assay
- —
- Laboratories named
- 0
- Median label gap
- —
- Median purity
- —
- Lowest price per mg
- $15.60
- peer median $15.60
- Publications located
- 50
- researched since 2021
Source: PepIndex, an independent index of research-peptide vendors. No vendor can pay for a rank, every score is computed by a published formula, and every figure links to the document it was read from.
No indexed vendor publishes a Mazdutide certificate naming a laboratory this index could check, so no vendor can be called well-tested for it yet. The lowest listed price is $15.60 per mg at Modern Aminos, against a peer median of $15.60. 1 vendor carrying Mazdutide is compared below. 0 publish at least one certificate naming a checkable laboratory, no lot record is on file, and none is an independently commissioned assay. Figures are PepIndex's own: it is an independent index of research-peptide vendors, no vendor can pay for a rank, and each figure links to the certificate it was read from.
Every vendor carrying Mazdutide
| # | Vendor | Score here | Price / mg | Lots | Newest test | Laboratory | Mean purity | Label gap | Reports |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Modern AminosISO/IEC 17025COAs need an account | 80.997% | $15.60 (100%) | 0 | — | — | — | — | no reportVisit site |
Independent assays
No independently commissioned assay of Mazdutide is on file. No certificate for it has been indexed at all. PepIndex does not yet commission its own assays, so nothing on this page establishes what is in a vial beyond the vendor’s own certificate. A record moves into this section the moment an assay commissioned by anyone other than the seller is indexed.
Laboratories used
No certificate for Mazdutide names a laboratory this index could identify.
Every certificate record
No certificate record for Mazdutide is indexed. Either no vendor publishes one, or those published could not be read without an account.
Score breakdown
The score has two halves: the research base — how long the compound has been studied and how much has been published — and the quality of the evidence the market produces for it, aggregated across every vendor that carries it: assayed purity, lot-to-lot consistency, readable third-party certificates and those vendors’ review record. It measures the evidence base, not the merits or safety of the substance.
Studied since 2021 — 5 years of published research
How long the compound has been studied. Fifteen years or more of published literature earns full marks; a newer compound earns less.
50 publications indexed in PubMed
The volume of published literature located. Full marks at fifty or more publications.
No certificate records indexed yet — nothing recorded yet
Average assayed purity on the certificates published by vendors that carry this compound. Full marks at 99.5%+, nothing at 95% or below.
No certificate records indexed yet — nothing recorded yet
How tightly assayed purity and labeled-versus-actual mass hold across different lots. Rewards reproducible manufacturing.
1 of 1 listing vendor publish an accessible certificate policy
Whether the vendors carrying this compound publish per-lot certificates anyone can read without an account.
No certificate records indexed yet — nothing recorded yet
Share of certificates issued by a recognised third-party testing lab rather than an unnamed or self-named one.
What is Mazdutide?
A GLP-1 and glucagon receptor dual agonist peptide developed for obesity and metabolic disease. It has been approved in China and remains investigational elsewhere.
Studied in published research for obesity and metabolic disease, as a GLP-1/glucagon dual agonist.
Regulatory status
Mazdutide is approved as a medicine in some countries but not in the United States. Products listed here are labeled by their vendors for laboratory research use only, and nothing here is medical advice.
What the research examines
The areas of published research this compound appears in. These describe what the literature has studied — never a claim of benefit, effect or suitability for any use.
Published research
PepIndex records the size and shape of the published research footprint only. It does not evaluate or summarise clinical significance, does not describe administration, and nothing here is a claim of safety or efficacy.
- Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight — The New England journal of medicine (2025)
Peer-reviewed article indexed in PubMed, published in The New England journal of medicine (2025).
- Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial — EClinicalMedicine (2022)
Peer-reviewed article indexed in PubMed, published in EClinicalMedicine (2022).
- Emerging pharmacotherapies for obesity: A systematic review — Pharmacological reviews (2025)
Peer-reviewed article indexed in PubMed, published in Pharmacological reviews (2025).
- A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity — Nature communications (2023)
Peer-reviewed article indexed in PubMed, published in Nature communications (2023).
- Mazdutide: First Approval — Drugs (2025)
Peer-reviewed article indexed in PubMed, published in Drugs (2025).
- Beyond weight loss: multisystem benefits of obesity medications — The lancet. Diabetes & endocrinology (2026)
Peer-reviewed article indexed in PubMed, published in The lancet. Diabetes & endocrinology (2026).
PepIndex describes what literature exists. We do not interpret it, assess clinical significance, or publish quantities, protocols or instructions for use.